Course
Atherosclerosis and Erectile Dysfunction, What’s the connection?
Course Highlights
- In this Atherosclerosis and Erectile Dysfunction, What’s the connection? course, we will learn about the association between erectile dysfunction and various underlying health conditions, including atherosclerosis.
- You’ll also learn the definition and prevalence of erectile dysfunction.
- You’ll leave this course with a broader understanding of the emotional distress erectile dysfunction can cause for both patients and their partners.
About
Contact Hours Awarded: 1
Course By:
Robert Hengsterman, MSN, RN, MA
Begin Now
Read Course | Complete Survey | Claim Credit
➀ Read and Learn
The following course content
Introduction
Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for sexual intercourse and an increasing health concern causing significant impact on the quality of life [1][6]. However, if left untreated, it can cause significant emotional distress for both the patient and their partner [3]. Erectile dysfunction can also be a sign of an underlying health condition that needs treatment and may increase an individual’s risk of heart disease [2]. Erectile dysfunction, sometimes referred to as impotence, is a prevalent condition affecting a significant proportion of men over 40 years of age worldwide [3]. While the exact definition of ED does not specify a specific time frame, experts suggest that the condition needs to persist for at least six months to be considered chronic [3].
ED is often associated with various underlying causes and is treatable. In 1995, an estimated 152 million men worldwide were affected by ED [5]. By 2025, projections indicate a significant rise in ED prevalence, reaching approximately 322 million men worldwide, representing an increase of nearly 170 million [5]. This growing trend is more pronounced in developing regions of Africa, Asia, and South America [5].
Atherosclerosis, or a hardening of the arteries due to plaque buildup, can impact sexual function and overall well-being [4]. This course delves into the intricate connection between atherosclerosis and ED, equipping nurses with the knowledge and skills to guide and educate their patients on prevention strategies, treatment options, and the restoration of sexual intimacy. Learners will be introduced to the evaluation and treatment of ED, emphasizing the crucial role of interprofessional collaboration in managing patients with this condition.
Self Quiz
Ask yourself...
- Considering the significant emotional distress ED can cause for both patients and their partners, why do you think men often hesitate to seek help for this condition?
- Given the increasing prevalence of ED and its association with underlying health conditions, what are the key challenges and opportunities in screening, evaluating, and treating ED in diverse healthcare settings?
Epidemiology of Atherosclerosis
Atherosclerosis, the progressive buildup of plaque in the coronary arteries, is a major underlying cause of cardiovascular diseases (CVDs), including coronary artery disease (CAD), stroke, and peripheral arterial disease (PAD) [15]. The global burned of atherosclerosis is estimated at 17.9 million deaths worldwide in 2019, representing almost one-third of all global deaths [16]. Understanding the epidemiology of atherosclerosis is crucial for developing effective preventive measures, optimizing treatment strategies, and allocating healthcare resources. Atherosclerosis, a build-up of fatty material called atheroma (or plaque), is a prevalent condition, affecting individuals of all ages, ethnicities, and socioeconomic backgrounds [19].
According to the American Heart Association (AHA), the likelihood of developing CVD in US men and women is 40% between the ages of 40 and 59, 75% between 60 and 79, and 86% for those over the age of 80 [18]. Patients from minority groups with acute coronary syndrome (ACS) are at an increased risk of heart attack (MI), readmission to the hospital, and death from ACS [17]. Black/African Americans are at 30% increased risk of heart disease and death from heart disease and double the risk of stroke with a higher risk of developing heart failure [17]. Among Asian Americans/Pacific Islanders, coronary artery disease (CAD) manifests earlier in life and affects a larger proportion of the population compared to other ethnic groups [17]. Overall CVD rates are lower among non-white Hispanic individuals. Among Hispanic subgroups, Puerto Rican Americans exhibit the highest HTN-related death rates [17]. And heart failure incidence among Hispanics falls between that of African Americans and non-Hispanic whites [17].
Self Quiz
Ask yourself...
- Given the significant global burden of atherosclerosis, what are the primary challenges in preventing and managing this disease in diverse populations worldwide?
- Considering the disproportionate burden of cardiovascular diseases among minority groups, what are the potential underlying factors contributing to these disparities and how can healthcare systems address them?
- With the advancement of medical technology and the development of new preventive and therapeutic interventions, how can we ensure that the benefits of these advancements reach underserved populations and contribute to reducing the global burden of atherosclerosis?
Epidemiology of Erectile Dysfunction
ED is a prevalent and complex medical condition with multiple contributing factors that impacts the lives of men worldwide. Recent epidemiological studies indicate that almost 10% of men between the ages of 40 and 70 experience severe or complete ED, categorized by the inability to achieve, or maintain erections for satisfactory sexual intercourse [7]. In addition, 25% of men in this age group experience moderate or intermittent erectile difficulties [7]. The prevalence of ED is age-dependent, with the combined prevalence of moderate to complete ED increasing from around 22% at age 40 to 49% by age 70 [7].
While less common in younger men, ED still affects 5% to 10% of men under the age of 40 [7]. These findings highlight the substantial impact of ED on men’s overall health and well-being, including mood, interpersonal functioning, and quality of life [6]. The most common risk factors include age, vascular disease, neurological disorders, psychological factors, lifestyle factors, and medications. Vascular disease and conditions that affect blood flow, such as atherosclerosis, hypertension, and diabetes, are major risk factors for ED [8]. Neurological conditions such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis can also contribute to ED [9]. Psychological distress, anxiety, and depression can affect sexual function and contribute to ED [10].
Modifiable lifestyle factors such as smoking, excessive alcohol consumption, and physical inactivity can increase the risk of ED [11]. Common medications, including antidepressants, antihypertensives, and antipsychotics, can have adverse effects on sexual function and contribute to ED with 5α-Reductase inhibitor (5-ARI) and neuropsychiatric medications having the highest reports of ED adverse effects [12]. Medication use may contribute to erectile dysfunction in up to 25% of cases [12].
There are regional variations in the prevalence and risk factors of ED which vary across different regions of the world. Studies suggest that ED is more prevalent in Asia compared to Europe or North America [14]. This variation is likely due to differences in lifestyle factors, healthcare access, and underlying medical conditions [14].
Self Quiz
Ask yourself...
- Given the substantial impact of ED on men’s overall health and well-being, what are the key challenges in screening, diagnosing, and treating ED in diverse populations worldwide?
- Considering the increasing prevalence of ED in younger age groups, what preventive measures can be implemented to reduce the risk of developing ED and promote lifelong sexual health?
- Given the regional variations in ED prevalence and risk factors, how can healthcare providers tailor their approaches to ED management to address the specific needs of different populations?
Pathophysiology of Atherosclerosis
Atherosclerosis, a progressive narrowing of the arteries, originates from endothelial disruption and damage to the thin layer of cells lining the inner surface of artery walls, known as the arterial intima [23]. Endothelial dysfunction impairs the regulation of blood vessel tone, blood clotting, and maintaining a smooth anti-thrombotic surface [24]. The disruption of the endothelium compromises its barrier function, enabling low-density lipoprotein (LDL) cholesterol particles, commonly known as “bad” cholesterol, to infiltrate the arterial wall. These LDL particles become entrapped within the intima, the innermost layer of the artery [20] [25].
Accumulation of LDL particles in macrophages triggers an inflammatory cascade causing macrophages to release inflammatory molecules that attract more monocytes and other immune cells to the site [26]. These immune cells further perpetuate the inflammatory response, leading to the formation of foam cells, macrophages laden with lipids [26].
Atherosclerosis, the underlying cause of most cardiovascular diseases, is a chronic progressive inflammatory disease characterized by the accumulation of lipids, fibrous elements, and calcification within the inner layers of arteries [20]. This buildup (plaque) over time narrows the artery lumen, restricting blood flow and increasing the risk of cardiovascular events such as heart attack, stroke, and peripheral artery disease [20][21].
The earliest lesions of atherosclerosis, known as fatty streaks, are characterized by the accumulation of cholesterol-engorged macrophages (foam cells) beneath the inner lining of the arteries [20] [21]. These lesions can appear in the aorta during the first decade of life, within the coronary arteries in the second decade, and the cerebral arteries in the third or fourth decades [21]. Fibroatheroma is the first advanced lesion of coronary atherosclerosis and is characterized by the proliferation of smooth muscle cells (SMCs) within the intima, which form a fibrous cap surrounding the foam cells [21]. This fibrous cap is composed of connective tissue, and it plays a role in protecting the underlying atherosclerotic plaque from rupture [22].
Differences in blood flow patterns contribute to the preferential formation of fatty streaks in specific locations within the arteries [20]. Fatty streaks are not of clinical significance, buy they represent the initial stage of atherosclerotic lesion development and serve as precursors to more advanced lesions characterized by the accumulation of lipid-rich necrotic debris and smooth muscle cells (SMCs) [20][22].
Plaque rupture is a critical, but common event in the pathogenesis of atherosclerosis and coronary thrombosis [25]. When the fibrous cap of a plaque ruptures, the underlying lipid core becomes exposed to the bloodstream which triggers platelet activation and thrombus formation, a blood clot that can obstruct blood flow and lead to a heart attack or stroke [22].
Self Quiz
Ask yourself...
- Given the role of endothelial dysfunction in initiating atherosclerosis, what are the key factors that contribute to endothelial damage and impairment?
- How does the accumulation of LDL cholesterol particles within the arterial wall contribute to the formation of atherosclerotic plaques?
- What are the distinguishing features of the different stages of atherosclerotic lesion development, from fatty streaks to advanced fibroatheromas?
- Given the critical role of plaque rupture in triggering coronary thrombosis, what factors contribute to plaque instability and increase the risk of rupture?
Pathophysiology of Erectile Dysfunction
The pathophysiology of ED requires an understanding of the intricate mechanisms and interactions of the somatic and autonomic nervous systems that orchestrate a male erection [28]. Impairments in endocrine, neural, or vascular systems, stemming from aging, medical conditions, neurological disorders, surgical procedures, or medications, can give rise to sexual dysfunctions and impact a patient’s quality of life [28].
Sexual arousal occurs in a cascade of neural mediated phenomena along with vascular and hormonal events [29]. The parasympathetic nervous system plays a crucial role in initiating and maintaining an erection, transmitting erection-inducing signals from the sacral spine to the penile blood vessels [30]. The sexual stimuli trigger the release of nitric oxide (NO) from non-adrenergic, non-cholinergic (NANC) nerves in the penis [31].
A normal erection ensues following the release of nitric oxide (NO) from non-adrenergic, non-cholinergic (NANC) nerve fibers. Nitric oxide (NO) is a powerful vasodilator, causing the smooth muscles in the penile arteries to relax, allowing blood to flow into the corpora cavernosa, which are sponge-like tissues that fill with blood during an erection [32]. The surge of blood flow causes the veins within the corpora cavernosa to become compressed, trapping blood within the penis and resulting in its engorgement and erection [33].
Alongside nitric oxide (NO), cyclic guanosine monophosphate (cGMP) plays a crucial role in maintaining an erection. cGMP acts as a secondary messenger, further enhancing smooth muscle relaxation and prolonging the erection [34] [35]. However, enzymes known as phosphodiesterase’s (PDEs) counteract cGMP by breaking it down, leading to the detumescence of the penis and the end of an erection [34]. Nitric Oxide (NO) and cGMP work together to initiate and maintain an erection, while phosphodiesterase’s (PDEs) work in opposition, breaking down cGMP and bringing about detumescence (the subsidence of a swelling). The delicate balance between NO, cGMP, and PDEs is essential for erectile health [35].
Self Quiz
Ask yourself...
- Considering the intricate interplay between the nervous, vascular, and hormonal systems in erectile function, how do impairments in any of these systems contribute to the development of erectile dysfunction?
- Given the crucial role of nitric oxide (NO), cyclic guanosine monophosphate (cGMP), and phosphodiesterase (PDE) enzymes in the erectile process, how do pharmacological interventions that target these molecules impact erectile function?
Link Between Atherosclerosis and Erectile Dysfunction
Atherosclerosis is a major risk factor and the most prevalent cause of ED [36]. The identical process that creates heart disease can cause erectile dysfunction which manifests earlier than heart disease. Erectile dysfunction is a vascular disorder that arises when plaque, a buildup of fatty deposits, cholesterol, and other substances, accumulates on the inner walls of the arteries [15]. As plaque thickens, it can narrow or even block the arteries, hindering systemic blood flow. Sufficient blood flow is crucial for an erection to occur and be sustained. When blood flow to the penis is restricted due to atherosclerosis, ED may develop.
Endothelial dysfunction plays a key role in the development of atherosclerosis and contributes to impaired blood flow to the heart and penis [37]. When the endothelium becomes dysfunctional, it can no longer produce nitric oxide (NO), a molecule that helps to relax blood vessels and promote blood flow [35]. This impaired blood flow can lead to a variety of health problems, including atherosclerosis, heart disease, and ED.
Self Quiz
Ask yourself...
- Given that atherosclerosis is a major risk factor for both heart disease and erectile dysfunction, what are the similarities and differences in the pathophysiology of these two conditions?
Prevention: A Proactive Approach
ED and heart disease have shared risk factors and lifestyle modifications techniques [38]. ED and heart disease are two prevalent health concerns that affect millions of individuals worldwide [4][5]. While these conditions may seem distinct, they share common underlying risk factors and can be prevented or delayed through similar lifestyle modifications.
Both ED and heart disease are influenced by a cluster of common risk factors, including smoking which damages the endothelium, high blood pressure which damages the delicate blood vessels supplying the penis, high cholesterol which can contribute to plaque accumulation and reduced blood flow, and diabetes which contributes to plaque buildup and nerve damage to key architecture that control erection [7][20][23][25]. Both conditions can be prevented or delayed by changes in lifestyle including smoking cessation, eating a heart healthy diet, exercising, and maintaining a healthy weight. Stress can also contribute to ED [10].
Self Quiz
Ask yourself...
- Considering the shared risk factors and lifestyle modification techniques for ED and heart disease, how can healthcare providers address these conditions to promote overall cardiovascular health and sexual well-being?
Treatment of Erectile Dysfunction
The treatment for ED treatment begins with addressing lifestyle factors such as obesity, inactivity, smoking, and alcohol use, as these can inhibit erectile function [7]. Weight management, regular physical activity, and smoking cessation are often the first steps, offering benefits beyond sexual health by improving overall cardiovascular well-being [10]. For many patients, oral medications such as sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) serve as the primary first line of pharmacological treatment [39]. These drugs, known as phosphodiesterase type 5 inhibitors (PDE5 inhibitors), enhance the effects of nitric oxide — a natural substance promoting muscle relaxation in the penis and increasing blood flow [40]. Intraurethral medications (transurethral agents) such as Alprostadil can be administered in pellet form, inserted into the urethra at the tip of the penis irrespective of ED origin.[48]
For ED linked to low testosterone levels, hormonal therapy may be prescribed. Testosterone therapy has been proven to increase libido, but not improve erectile dysfunction [41][42]. Psychological factors such as stress and depression can contribute to ED, making psychological counseling an effective component of a comprehensive treatment plan for erectile dysfunction [10][43].
In patients where medication is ineffective or unsuitable, other treatments include vacuum erection devices, intracavernous injection therapy with drugs like alprostadil, or intraurethral alprostadil [44]. Surgical options for ED, such as penile implants, are considered the last resort due to their invasive nature and risk of complications [45]. Some individuals explore alternative therapies, including supplements and acupuncture, but these require caution due to potential interactions and variable efficacy [46]. Vacuum Constriction Devices (VCD) are non-invasive mechanical devices capable of producing an erection [47]. The device consists of a tube that is placed over the penis, a pump to create a vacuum that draws blood into the penis, and a ring that is placed around the base of the penis to maintain the erection.
Self Quiz
Ask yourself...
- Considering the multifactorial causes of erectile dysfunction, how might lifestyle changes alone, such as weight management and smoking cessation, impact the efficacy of pharmacological treatments like PDE5 inhibitors?
- Given the range of treatment options available for erectile dysfunction, from oral medications to surgical interventions, how should a patient and healthcare provider approach the decision-making process to determine the most appropriate and effective treatment plan?
Patient Education
Patient education is a critical component in the management of ED, which comprises imparting knowledge about the condition, its causes, treatment options, and the importance of lifestyle modifications. Patient education is an integral component of ED management, complementing pharmacological interventions [41].
For healthcare professionals, educating patients about the physiology of an erection and the various factors that can contribute to ED is fundamental. Patient education regarding potential side effects is essential for promoting medication compliance and improving patient outcomes [49]. Patients should be informed that ED can stem from a combination of psychological factors, such as stress and anxiety and physical conditions like diabetes and heart disease [10]. Education requires open communication about the potential influence of medications, substance use, and other underlying medical issues contributing to ED.
Patients should be informed about the profound impact of lifestyle choices on erectile function [50]. Education should also emphasize the positive ripple effects of these changes on overall health and cardiovascular well-being. Educating patients on the importance of adhering to prescribed medications and understanding their interactions is vital, with the consideration that ED medications can have serious interactions with nitrates and certain other drugs. Education should not be a one-time event but an ongoing process because chronic health conditions that contribute to ED, such as diabetes and hypertension, require consistent management, and patients should understand how addressing these conditions can improve erectile symptoms [51].
A patient’s belief in their ability to achieve their wellness goals impacts their approach to health-related objectives, tasks, and challenges. Lifestyle interventions have demonstrated clinical benefits in a diverse range of conditions, including diabetes, coronary heart disease, heart failure, and rheumatoid arthritis [51].
Self Quiz
Ask yourself...
- How does a patient’s understanding of the physiological and psychological factors contributing to erectile dysfunction influence their commitment to a long-term treatment regimen, including lifestyle modifications?
- In what ways can continuous patient education on medication adherence and the management of chronic health conditions that contribute to erectile dysfunction lead to improved outcomes, and how can healthcare providers facilitate this ongoing educational process?
Conclusion
Erectile dysfunction can impact a patient’s quality of life and relationships, but there are multiple treatment options available. The choice of treatment is a joint decision between the patient and healthcare provider, considering the cause of ED, patient preference, cost, ease of use, and potential side effects. A collaborative care approach, involving a team of healthcare professionals, ensures a multifaceted treatment strategy tailored to the patient’s individual needs. Regular monitoring and follow-up are crucial for assessing the effectiveness of the treatment, managing its side effects, and adapting to any changes in the patient’s condition or preferences [52].
References + Disclaimer
- Rew, K. T., & Heidelbaugh, J. J. (2016). Erectile dysfunction. American Family Physician, 94(10), 820–827. https://www.aafp.org/pubs/afp/issues/2016/1115/p820.html
- Mayo Clinic. (2022). Erectile dysfunction – Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/erectile-dysfunction/symptoms-causes/syc-20355776
- Leslie, S. W., & Sooriyamoorthy, T. (2023). Erectile dysfunction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK562253/
- Tsujimura, A., Hiramatsu, I., Aoki, Y., Shimoyama, H., Mizuno, T., Nozaki, T., Shirai, M., Kobayashi, K., Kumamoto, Y., & Horie, S. (2017). Atherosclerosis is associated with erectile function and lower urinary tract symptoms, especially nocturia, in middle-aged men. Prostate International, 5(2), 65–69. https://doi.org/10.1016/j.prnil.2017.01.006
- Aytaç, Mckinlay, K. (2001). The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International, 84(1), 50–56. https://doi.org/10.1046/j.1464-410x.1999.00142.x
- Huri, H. Z., Sanusi, N. D. M., Razack, A. H. A., & Mark, R. (2016). Association of psychological factors, patients’ knowledge, and management among patients with erectile dysfunction. Patient Preference and Adherence, 807. https://doi.org/10.2147/ppa.s99544
- Boston University School of Medicine. (2002). Epidemiology of ED. Boston University School of Medicine: Sexual Medicine. https://www.bumc.bu.edu/sexualmedicine/physicianinformation/epidemiology-of-ed/
- Ibrahim, A., Ali, M., Kiernan, T. J., & Stack, A. G. (2018). Erectile dysfunction and ischaemic heart disease. European Cardiology, 13(2), 1. https://doi.org/10.15420/ecr.2017.21.3
- American Academy of Neurology. (2023). Erectile dysfunction, often overlooked in neurological disorders, is treatable. Neurology Today. https://journals.lww.com/neurotodayonline/fulltext/2003/08000/erectile_dysfunction,_often_overlooked_in.14.aspx
- Xiao, Y., Xie, T., Peng, J., Zhou, X. Y., Long, J., Yang, M., Zhu, H., & Yang, J. (2023). Factors associated with anxiety and depression in patients with erectile dysfunction: a cross-sectional study. BMC Psychology, 11(1). https://doi.org/10.1186/s40359-023-01074-w
- Maiorino, M. I., Bellastella, G., & Esposito, K. (2015). Lifestyle modifications and erectile dysfunction: what can be expected? Asian Journal of Andrology, 17(1), 5. https://doi.org/10.4103/1008-682x.137687
- Kaplan-Marans, E., Sandozi, A., Martinez, M., Lee, J., Schulman, A., & Khurgin, J. (2022). Medications most commonly associated with erectile dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database. Sexual Medicine, 10(5), 100543. https://doi.org/10.1016/j.esxm.2022.100543
- Keene, L. C., & Davies, P. H. (1999). Drug-related erectile dysfunction. Adverse Drug Reactions and Toxicological Reviews, 18(1), 5–24. https://pubmed.ncbi.nlm.nih.gov/10401520/
- Irfan, M., Hussain, N. H. N., Norhayati, M. N., Mohamed, M., Sidi, H., & Ismail, S. (2020). Epidemiology of male sexual dysfunction in Asian and European regions: A systematic review. American Journal of Men’s Health, 14(4), 155798832093720. https://doi.org/10.1177/1557988320937200
- National Heart, Lung, and Blood Institute, National Institute of Health. (2022). Atherosclerosis: What is atherosclerosis? https://www.nhlbi.nih.gov/health/atherosclerosis
- World Health Organization. (2021). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- Graham, G. (2015). Disparities in cardiovascular disease risk in the United States. Current Cardiology Reviews, 11(3), 238–245. https://doi.org/10.2174/1573403×11666141122220003
- Yazdanyar, A., & Newman, A. B. (2009). The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs. Clinics in Geriatric Medicine, 25(4), 563–vii. https://doi.org/10.1016/j.cger.2009.07.007
- British Heart Foundation. (2023). Atherosclerosis. https://www.bhf.org.uk/informationsupport/conditions/atherosclerosis
- Lusis, A. J. (2000). Atherosclerosis. Nature, 407(6801), 233–241. https://doi.org/10.1038/35025203
- Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013). Macrophages in atherosclerosis: A dynamic balance. Nature Reviews Immunology, 13(10), 709–721. https://doi.org/10.1038/nri3520
- Loftus, I. (2011). Mechanisms of plaque rupture. In: Fitridge, R., Thompson, M., eds. Mechanisms of vascular disease: A reference book for vascular specialists [Internet]. Adelaide (AU): University of Adelaide Press. https://www.ncbi.nlm.nih.gov/books/NBK534259/
- Gimbrone, M. A., & Garcı́a-Cardeña, G. (2016). Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circulation Research, 118(4), 620–636. https://doi.org/10.1161/circresaha.115.306301
- Rajendran, P., Rengarajan, T., Jayakumar, T., Nishigaki, Y., Sakthisekaran, D., Sethi, G., & Nishigaki, I. (2013). The vascular endothelium and human diseases. International Journal of Biological Sciences, 9(10), 1057–1069. https://doi.org/10.7150/ijbs.7502
- Falk, E. (2006). Pathogenesis of atherosclerosis. Journal of the American College of Cardiology, 47(8), C7–C12. https://doi.org/10.1016/j.jacc.2005.09.068
- Linton, M. R. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W. L., Doran, A. C., & Vickers, K. C. (2019). The role of lipids and lipoproteins in atherosclerosis. In: Feingold, K. R., Anawalt, B., Blackman, M. R., et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK343489/
- Lee-Rueckert, M., Lappalainen, J., Kovanen, P. T., & Escolà‐Gil, J. C. (2022). Lipid-laden macrophages and inflammation in atherosclerosis and cancer: An integrative view. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.777822
- Calabrò, R. S., Cacciola, A., Bruschetta, D., Milardi, D., Quattrini, F., Sciarrone, F., La Rosa, G., Bramantı, P., & Anastasi, G. (2019). Neuroanatomy and function of human sexual behavior: A neglected or unknown issue? Brain and Behavior, 9(12). https://doi.org/10.1002/brb3.1389
- Azadzoi, K. M., Yang, J., & Siroky, M. B. (2013). Neural regulation of sexual function in men. World Journal of Clinical Urology, 2(3), 32. https://doi.org/10.5410/wjcu.v2.i3.32
- Goldstein, I. (2003). The central mechanisms of sexual function. Boston University School of Medicine: Sexual Medicine. https://www.bumc.bu.edu/sexualmedicine/publications/the-central-mechanisms-of-sexual-function/
- Yafi, F. A., Jenkins, L. C., Albersen, M., Corona, G., Isidori, A. M., Goldfarb, S., Maggi, M., Nelson, C. J., Parish, S. J., Salonia, A., Tan, R., Mulhall, J. P., & Hellstrom, W. J. (2016). Erectile dysfunction. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.3
- Davies, K. P. (2015). Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction. Future Science OA, 1(1). https://doi.org/10.4155/fso.15.53
- Panchatsharam, P. K., Durland, J., & Zito, P. M. (2023). Physiology, erection. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK513278/
- Burnett, A. L. (2006). The role of nitric oxide in erectile dysfunction: Implications for medical therapy. Journal of Clinical Hypertension, 8(s12), 53–62. https://doi.org/10.1111/j.1524-6175.2006.06026.x
- Melis, M. R., & Argiolas, A. (2021). Erectile function and sexual behavior: A review of the role of nitric oxide in the central nervous system. Biomolecules, 11(12), 1866. https://doi.org/10.3390/biom11121866
- Schwartz, B. G., & Kloner, R. A. (2011). Cardiovascular implications of erectile dysfunction. Circulation, 123(21). https://doi.org/10.1161/circulationaha.110.017681
- Mayo Clinic. (2022). Erectile dysfunction: A sign of heart disease? https://www.mayoclinic.org/diseases-conditions/erectile-dysfunction/in-depth/erectile-dysfunction/art-20045141
- Jackson, G. (2013). Erectile dysfunction and cardiovascular disease. Arab Journal of Urology, 11(3), 212–216. https://doi.org/10.1016/j.aju.2013.03.003
- Mayo Clinic. (2023). Erectile dysfunction: Viagra and other oral medications. https://www.mayoclinic.org/diseases-conditions/erectile-dysfunction/in-depth/erectile-dysfunction/art-20047821
- Huang, S. A., & Lie, J. D. (2013). Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P & T : A Peer-reviewed Journal for Formulary Management, 38(7), 407–419. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776492/
- Rizk, P., Kohn, T. P., Pastuszak, A. W., & Khera, M. (2017). Testosterone therapy improves erectile function and libido in hypogonadal men. Current Opinion in Urology, 27(6), 511–515. https://doi.org/10.1097/mou.0000000000000442
- Petering, R. C., & Brooks, N. (2017). Testosterone therapy: Review of clinical applications. American Family Physician. https://www.aafp.org/pubs/afp/issues/2017/1001/p441.html
- Dewitte, M., Bettocchi, C., Carvalho, J., Corona, G., Flink, I., Limoncin, E., Pascoal, P. M., Reisman, Y., & Van Lankveld, J. (2021). A psychosocial approach to erectile dysfunction: Position statements from the European Society of Sexual Medicine (ESSM). Sexual Medicine, 9(6), 100434. https://doi.org/10.1016/j.esxm.2021.100434
- Kava B. R. (2005). Advances in the management of post-radical prostatectomy erectile dysfunction: Treatment strategies when PDE-5 inhibitors don’t work. Reviews in Urology, 7(Suppl 2), S39–S50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477601/
- Frydman, V., Pinar, U., Abdessater, M., Akakpo, W., Grande, P., Audouin, M., Mozer, P., Chartier‐Kastler, E., Seisen, T., & Rouprêt, M. (2021). Long-term outcomes after penile prosthesis placement for the management of erectile dysfunction: A single-centre experience. Basic and Clinical Andrology, 31(1). https://doi.org/10.1186/s12610-021-00123-x
- Guo, J., & Wang, F. (2022). The efficacy of acupuncture on patients with erectile dysfunction: A review. Evidence-based Complementary and Alternative Medicine, 1–10. https://doi.org/10.1155/2022/4807271
- Trost, L., Munárriz, R., Wang, R., Morey, A. F., & Levine, L. A. (2016). External mechanical devices and vascular surgery for erectile dysfunction. The Journal of Sexual Medicine, 13(11), 1579–1617. https://doi.org/10.1016/j.jsxm.2016.09.008
- Costa, P., & Potempa, A. (2012). Intraurethral alprostadil for erectile dysfunction. Drugs, 72(17), 2243–2254. https://doi.org/10.2165/11641380-000000000-00000
- Huri, H. Z., Sanusi, N. D. M., Razack, A. H. A., & Mark, R. (2016). Association of psychological factors, patients’ knowledge, and management among patients with erectile dysfunction. Patient Preference and Adherence, 807. https://doi.org/10.2147/ppa.s99544
- Maiorino, M. I., Bellastella, G., & Esposito, K. (2015). Lifestyle modifications and erectile dysfunction: What can be expected? Asian Journal of Andrology, 17(1), 5. https://doi.org/10.4103/1008-682x.137687
- Paterick, T. E., Patel, N., Tajik, A. J., & Chandrasekaran, K. (2017). Improving health outcomes through patient education and partnerships with patients. Baylor University Medical Center Proceedings, 30(1), 112–113. https://doi.org/10.1080/08998280.2017.11929552
- Jannini, E. A., & Droupy, S. (2018). Needs and expectations of patients with erectile dysfunction: An update on pharmacological innovations in phosphodiesterase type 5 inhibition with focus on Sildenafil. Sexual Medicine, 7(1), 1–10. https://doi.org/10.1016/j.esxm.2018.10.005
Disclaimer:
Use of Course Content. The courses provided by NCC are based on industry knowledge and input from professional nurses, experts, practitioners, and other individuals and institutions. The information presented in this course is intended solely for the use of healthcare professionals taking this course, for credit, from NCC. The information is designed to assist healthcare professionals, including nurses, in addressing issues associated with healthcare. The information provided in this course is general in nature and is not designed to address any specific situation. This publication in no way absolves facilities of their responsibility for the appropriate orientation of healthcare professionals. Hospitals or other organizations using this publication as a part of their own orientation processes should review the contents of this publication to ensure accuracy and compliance before using this publication. Knowledge, procedures or insight gained from the Student in the course of taking classes provided by NCC may be used at the Student’s discretion during their course of work or otherwise in a professional capacity. The Student understands and agrees that NCC shall not be held liable for any acts, errors, advice or omissions provided by the Student based on knowledge or advice acquired by NCC. The Student is solely responsible for his/her own actions, even if information and/or education was acquired from a NCC course pertaining to that action or actions. By clicking “complete” you are agreeing to these terms of use.
➁ Complete Survey
Give us your thoughts and feedback
➂ Click Complete
To receive your certificate